News articles about Akorn (NASDAQ:AKRX) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akorn earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.6192834406569 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- What Does Technical Indicators say About Akorn, Inc. (NASDAQ:AKRX)? – The Oracle Examiner (oracleexaminer.com)
- Akorn, Inc. – Value Analysis (NASDAQ:AKRX) : October 16, 2017 (finance.yahoo.com)
- Allergan settles with one of four companies contesting Restasis patent (AGN, TEVA, AKRX, MYL) (uk.news.yahoo.com)
- Akorn, Inc. breached its 50 day moving average in a Bullish Manner : AKRX-US : October 13, 2017 (finance.yahoo.com)
Shares of Akorn (NASDAQ AKRX) opened at 33.25 on Wednesday. The stock has a 50 day moving average of $33.00 and a 200 day moving average of $32.77. The company has a market cap of $4.15 billion, a price-to-earnings ratio of 33.59 and a beta of 1.40. Akorn has a 12-month low of $17.61 and a 12-month high of $34.00.
A number of analysts have issued reports on the stock. Jefferies Group LLC reiterated a “hold” rating and issued a $34.00 price target on shares of Akorn in a report on Wednesday, July 19th. Royal Bank Of Canada set a $34.00 target price on shares of Akorn and gave the stock a “hold” rating in a report on Sunday, July 30th. BidaskClub downgraded shares of Akorn from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. TheStreet downgraded shares of Akorn from a “b-” rating to a “c” rating in a report on Tuesday, August 1st. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $34.00 target price on shares of Akorn in a report on Thursday, August 10th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. Akorn has a consensus rating of “Hold” and an average price target of $28.56.
ILLEGAL ACTIVITY NOTICE: “Akorn (NASDAQ:AKRX) Getting Somewhat Positive Media Coverage, Study Shows” was published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/akorn-akrx-receives-daily-media-sentiment-rating-of-0-16/1700832.html.
In related news, COO Bruce Kutinsky sold 40,000 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $33.46, for a total transaction of $1,338,400.00. Following the completion of the sale, the chief operating officer now owns 317,480 shares of the company’s stock, valued at approximately $10,622,880.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Brian Tambi sold 5,165 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $33.37, for a total transaction of $172,356.05. The disclosure for this sale can be found here. Insiders own 28.20% of the company’s stock.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with our FREE daily email newsletter.